{"id":"f520","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"F520 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"F520 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:24.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06226350","phase":"PHASE2","title":"A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2021-03-04","conditions":"Cervical Cancer","enrollment":29},{"nctId":"NCT05741021","phase":"PHASE2","title":"A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2023-03-01","conditions":"Non-small Cell Lung Cancer, NSCLC, PD-1","enrollment":84},{"nctId":"NCT05740215","phase":"PHASE1, PHASE2","title":"Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-23","conditions":"Solid Tumors","enrollment":158},{"nctId":"NCT05178836","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-01-01","conditions":"RR DLBCL; PD-1; CD20","enrollment":62},{"nctId":"NCT04636515","phase":"PHASE2","title":"A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2021-01","conditions":"Locally Advanced or Metastatic Urothelial Cell Carcinoma","enrollment":80},{"nctId":"NCT04457830","phase":"PHASE2","title":"The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2020-11-01","conditions":"Peripheral T Cell Lymphoma","enrollment":105},{"nctId":"NCT03657381","phase":"PHASE1","title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2019-03-01","conditions":"Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT04457869","phase":"PHASE2","title":"A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2020-11-01","conditions":"Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rulonilimab"],"phase":"phase_2","status":"active","brandName":"F520","genericName":"F520","companyName":"Shandong New Time Pharmaceutical Co., LTD","companyId":"shandong-new-time-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"F520 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}